Who are Anelazol Sodium Enteric-coated Tablets's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/anelazol-sodium-enteric-coated-tablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Anelazol Sodium Enteric-coated Tablets — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anelazol Sodium Enteric-coated Tablets (Anelazol Sodium Enteric-coated Tablets) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Leukotriene inhibitor / Anti-inflammatory agent. Area: Immunology / Inflammatory diseases.

marketed Leukotriene inhibitor / Anti-inflammatory agent Leukotriene synthesis pathway Immunology / Inflammatory diseases Small molecule Live · refreshed every 30 min

Target snapshot

Anelazol Sodium Enteric-coated Tablets (Anelazol Sodium Enteric-coated Tablets) — Xuanzhu Biopharmaceutical Co., Ltd.. Anelazol sodium is an anti-inflammatory agent that inhibits leukotriene synthesis and reduces inflammatory mediator production.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Anelazol Sodium Enteric-coated Tablets TARGET	Anelazol Sodium Enteric-coated Tablets	Xuanzhu Biopharmaceutical Co., Ltd.	marketed	Leukotriene inhibitor / Anti-inflammatory agent	Leukotriene synthesis pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Leukotriene inhibitor / Anti-inflammatory agent class)

Xuanzhu Biopharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Anelazol Sodium Enteric-coated Tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/anelazol-sodium-enteric-coated-tablets. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab